MNG1159
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.363
- PANCREAS_BETA_CELLS+0.251
- ALLOGRAFT_REJECTION+0.231
- MYOGENESIS+0.229
- COAGULATION+0.226
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.208
- APICAL_SURFACE+0.157
- IL6_JAK_STAT3_SIGNALING+0.113
- SPERMATOGENESIS+0.091
- INFLAMMATORY_RESPONSE+0.055
Top 10 suppressed
- PROTEIN_SECRETION-0.620
- MYC_TARGETS_V1-0.539
- MTORC1_SIGNALING-0.513
- E2F_TARGETS-0.512
- OXIDATIVE_PHOSPHORYLATION-0.499
- G2M_CHECKPOINT-0.497
- UNFOLDED_PROTEIN_RESPONSE-0.488
- MITOTIC_SPINDLE-0.476
- NOTCH_SIGNALING-0.446
- ADIPOGENESIS-0.418
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG1245 | — | — | 0.941 |
| 2 | MNG923 | — | — | 0.936 |
| 3 | MNG1148 | — | — | 0.935 |
| 4 | MNG436 | — | — | 0.934 |
| 5 | MDT-AP-1143 | Med | Medulloblastoma | 0.933 |
| 6 | SRR1337431 | GTEX | — | 0.928 |
| 7 | SRR1448226 | GTEX | — | 0.927 |
| 8 | MNG1137 | — | — | 0.927 |
| 9 | MNG441 | — | — | 0.927 |
| 10 | SRR1419714 | GTEX | — | 0.925 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 12 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.363 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.251 | Cobimetinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.231 | Idelalisib | — uncovered |
| MYOGENESIS | 0.229 | Inavolisib | — uncovered |
| COAGULATION | 0.226 | Binimetinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.208 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.157 | Temsirolimus | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.113 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.091 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.055 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.018 | Remibrutinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.010 | Idelalisib | — uncovered |